Cwm LLC Increases Position in Twist Bioscience Corporation (NASDAQ:TWST)

CWM LLC grew its stake in Twist Bioscience Corporation (NASDAQ:TWST - Free Report) by 161.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 16,272 shares of the company's stock after buying an additional 10,048 shares during the period. CWM LLC's holdings in Twist Bioscience were worth $639,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in TWST. Versant Capital Management Inc raised its position in shares of Twist Bioscience by 547.2% in the first quarter. Versant Capital Management Inc now owns 686 shares of the company's stock worth $27,000 after acquiring an additional 580 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Twist Bioscience by 68.1% in the 1st quarter. GAMMA Investing LLC now owns 748 shares of the company's stock worth $29,000 after acquiring an additional 303 shares during the last quarter. Banque Transatlantique SA purchased a new position in Twist Bioscience in the 4th quarter valued at approximately $43,000. GF Fund Management CO. LTD. acquired a new stake in shares of Twist Bioscience in the 4th quarter valued at $58,000. Finally, Pallas Capital Advisors LLC acquired a new stake in Twist Bioscience during the 1st quarter worth $201,000.

Insider Activity at Twist Bioscience

In related news, COO Patrick John Finn sold 1,877 shares of the company's stock in a transaction on Wednesday, May 21st. The stock was sold at an average price of $29.75, for a total value of $55,840.75. Following the transaction, the chief operating officer directly owned 240,783 shares of the company's stock, valued at $7,163,294.25. This represents a 0.77% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Paula Green sold 1,101 shares of the firm's stock in a transaction dated Monday, May 5th. The shares were sold at an average price of $37.65, for a total value of $41,452.65. Following the sale, the senior vice president owned 129,380 shares in the company, valued at $4,871,157. This trade represents a 0.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 22,903 shares of company stock valued at $794,706 over the last 90 days. Insiders own 3.01% of the company's stock.

Twist Bioscience Trading Up 2.6%

TWST stock traded up $0.91 during trading on Friday, hitting $35.99. 871,922 shares of the company traded hands, compared to its average volume of 1,082,376. Twist Bioscience Corporation has a 1 year low of $27.12 and a 1 year high of $60.90. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.24 and a current ratio of 4.51. The company has a 50-day moving average of $34.03 and a 200-day moving average of $39.19. The firm has a market capitalization of $2.16 billion, a PE ratio of -11.07 and a beta of 2.41.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.10). The business had revenue of $92.79 million during the quarter, compared to the consensus estimate of $92.00 million. Twist Bioscience had a negative return on equity of 33.48% and a negative net margin of 54.98%. Analysts predict that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently commented on TWST shares. Barclays decreased their price objective on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a report on Thursday, April 10th. Robert W. Baird dropped their target price on shares of Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a report on Tuesday, May 6th. The Goldman Sachs Group dropped their target price on shares of Twist Bioscience from $55.00 to $48.00 and set a "buy" rating on the stock in a report on Tuesday, May 6th. JPMorgan Chase & Co. dropped their target price on shares of Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating on the stock in a report on Tuesday, May 6th. Finally, Guggenheim reissued a "buy" rating and set a $50.00 target price on shares of Twist Bioscience in a report on Tuesday, May 6th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, Twist Bioscience has a consensus rating of "Moderate Buy" and a consensus price target of $50.40.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.